INTRODUCTION
Gastrointestinal stromal tumor (GIST) is one of the most common malignant subepithelial lesions (SELs) of the stomach, and is pathologically defined by spindle cells, epitheloid cells or mixed ndings with positive immunostaining for c-kit or CD34 [1] [2] [3] [4] [5] [6] . Gastrointestinal stromal tumors have a risk of metastatic relapse, specifically in the liver and peritoneum, a er initial surgery for localized disease [2] [3] [4] [5] [6] [7] . e postoperative metastatic rate is related to tumor size and mitotic activity [5] .
Usually, the larger the tumor size, the more frequent the mitosis of the resected specimen and the higher the postoperative metastatic rate. e nature and frequency of the GIST among gastric SELs smaller than 2 cm is unknown. Furthermore, strict discrimination between benign and malignant GIST is considered to be very di cult both by imaging investigations and by pathological examinations even though benign GIST may exist. Therefore, the European Society for Medical Oncology (ESMO) as well as the Japanese GIST guidelines recommend surgical resection when SEL is diagnosed as immunohistologically con rmed GIST even if < 2 cm [8] [9] [10] . Furthermore, at present, there is no reliable clinical management algorithm for gastric SELs smaller than 2 cm [2, [7] [8] [9] . Miettinen et al reported that gastric GISTs smaller than 2cm have a 0% metastatic rate a er complete surgical resection irrespective of mitotic activity [5] . eoretically, early diagnosis of tumors smaller than 2 cm and early surgical resection is a promising way of obtaining a permanent cure of this disease.
EUS and EUS-FNA procedures
Standard EUS was performed on an outpatient basis, with the patient under conscious sedation, using a conventional radial scanner echoendoscope GF-UM20 (Olympus, Tokyo, Japan), EG-530UR2 (Fujifilm, Tokyo, Japan) or 12MHz ultrasound catheter probe SP-702 (Fuji lm, Tokyo, Japan). EUS-FNA was performed on a one day inpatient basis, with conscious sedation, using PEF-708FA (Toshiba-Fujinon, Tokyo, Japan) or EG-530UT2 (Fuji lm, Tokyo, Japan) convex array echoendoscope. e echoendoscope was connected to ultrasound scanner SSA-550A (Toshiba, Tokyo, Japan) or SU-8000 (Fuji lm, Tokyo, Japan). Color ow and Doppler sonography were performed to exclude intervening vascular structures and to select a vessel-free needle track. FNA procedures were performed using the 22G (NA-11J-KB, NA-200H, or EZ shot2, Olympus, Tokyo) or 25G needle (Expect, Boston Scienti c, USA). Once the tip of the catheter was visualized, the needle was advanced from the catheter sheath through the gastric wall and into the target lesion under EUS guidance. e stylet was removed and continuous suction applied with a 20-ml syringe. e needle was moved back and forth within the lesion under ultrasonographic guidance. e suction was then released and the needle removed from the working channel. e aspirates were placed on glass slides, and both air-dried and alcohol-xed smears were prepared. Air dried smears were stained with a modi ed Giemsa stain and reviewed immediately by a cytopathologist on site to ensure specimen adequacy. e remaining prepared histologic specimens were later processed for cell block in the pathology laboratory for hematoxylin and eosin staining and additional ancillary studies such as immunochemistry. e diagnosis of SEL using EUS-FNA in all cases was made by histologic assessment only. Subsequent hematocrit was obtained on the rst day a er EUS-FNA, and patients were assessed for hematemesis before discharge. If unsuccessful EUS-FNA was encountered, we performed the additional EUS-FNA session several months later to obtain an adequate sample. One attending endosonographer (KA) performed all EUS and EUS-FNA procedures. Technical data for EUS-FNA, including the date, age of the patients, type of needle, number of the needle pass, number of the session, location and size of the tumor, the Fig. 1 . Diagnostic and therapeutic algorithm for gastric subepithelial lesions (SELs) using endoscopic ultrasound-guided ne needle aspiration. Quoted and modi ed from Ref. [7] . In our institute, surgical resection is recommended for the patient with any size of histologically con rmed GIST (immunohistochemical analysis of the specimen obtained by EUS-FNA or bite-biopsy) according to the Japanese GIST guidelines [9] a er discussion with each patient. results of immunohistochemical analysis, and complications were recorded prospectively using our institutional formatted EUS-FNA reporting system.
Immunohistochemical analysis
Both the EUS-FNA and surgical resection specimens were xed in 10% formaldehyde and tissue blocks were embedded in para n. Sections were stained with hematoxylin and eosin. Immunoperoxidase stains were subsequently made on the cell block and representative histologic sections of the tumor using commercially available antibodies. Details of the antibodies are described elsewhere [9] . A tumor with positive reaction to c-kit and/or CD34 was diagnosed as GIST. A tumor with a negative reaction to c-kit, CD34, and S-100 and a positive reaction for muscle actin was diagnosed as a myogenic tumor (leiomyoma). A tumor with a negative reaction to c-kit, CD34, and muscle actin and positive reaction for S-100 was diagnosed as a neurogenic tumor (neurinoma).
Assessment of clinical outcome
Clinical management was performed according to our institutional management algorithm for gastrointestinal (GI) tract SEL ( Fig. 1 ) [7] . EUS-FNA diagnoses were compared with final diagnoses, which were based on the histologic examination of surgically resected pathology materials and/ or clinical follow-up (mean: 35 months, range: 2 to 108 months) ndings. A follow up study was performed using esophagogastroduodenoscopy (EGD) and US and/or CT. Histological diagnostic rate, complications, and the results of the follow-up study were evaluated in all 90 cases. Accuracy for the di erential diagnosis of SEL was calculated in 44 surgically resected cases which were conclusively diagnosed by preoperative EUS-FNA. e appropriate decision-making rate for management was calculated in the 66 diagnostic cases (excluding 24 unsuccessful EUS-FNA cases, as they were nondiagnostic).
Ethical considerations
is study was carried out only at Aso Iizuka Hospital and was approved by its Ethics Committee. Written informed consent was obtained from all the patients in accordance with the Declaration of Helsinki.
RESULTS
Clinicopathological characteristics of the lesions are summarized in Table I . Histological diagnosis of gastric SELs smaller than 2 cm by EUS-FNA were 47 malignant SELs (71%) consisting of 44 GISTs (Fig. 2 ), 1 SEL-like cancer, 1 glomus tumor, and 1 malignant lymphoma (Fig. 3) , and 19 benign SELs (29%) consisting of 14 leiomyomas, 4 ectopic pancreas (Fig. 4) , and 1 neurinoma. e remaining 24 SELs were not concluded by EUS-FNA. Forty-three out of 90 cases were diagnosed as GIST by postoperative immunohistochemical analysis. eir mitotic count were < 5/50 high power eld (HPF) (very low risk according to modified-Fletcher's classi cation) in 33 cases (77%) and >5/50 HPF (moderate risk according to modi ed-Fletcher's classi cation) in 10 cases (23%) [15] .
Technical results are shown in Table II . In one case, puncture was not performed because of poor EUS visualization due to severe intratumoral calci cation. e diagnostic rate ( rst session only) was 62% (56 of 90 patients). e diagnostic rate including the additional sessions completed after previous failure was improved to 73% (66 of 90 patients). No complications were encountered.
In 44 surgically resected cases a er conclusive EUS-FNA (excluding non-diagnostic EUS-FNA cases), the accuracy of the preoperative di erential diagnosis of SEL by EUS-FNA using immunohistochemical analysis was 98% (43 of 44 patients). Figure 5 shows EUS-FNA diagnosis, the following management, and the clinical course. Local resection was performed in 42 out of 44 patients diagnosed as GIST by EUS-FNA (Fig. 2) . Forty one out of 42 patients were diagnosed as GIST and the remaining patient was diagnosed as leiomyoma by postoperative immunohistochemical analysis. e 2 patients refused surgery. Appropriate management, including no need for treatment (Fig. 4) , surgery, and chemotherapy (Fig.  3 ) was performed in all 22 patients diagnosed as non-GIST. A er surgery, there was no recurrence in 47 malignant SELs. Appropriate management, including surgery, chemotherapy, and follow-up were performed in 65 out of 66 (98%) SELs diagnosed by de nitive EUS-FNA (Table III) . It was impossible to diagnose the remaining 24 patients because of insu cient material, but 22 patients were carefully followed up and two patients (patient's wish) received local resection (postoperative diagnosis for both was GIST). ere was no tumor growth or metastasis in any of the 24 undiagnosed cases in the follow up study.
DISCUSSION
Gastrointestinal stromal tumors are the most commonly identi ed malignant SELs in the stomach. eir malignancy potential varies. Large GISTs and GISTs with a high mitosis count have a high recurrence rate, with metastases typically in the liver and abdominal cavity [1] [2] [3] [4] [5] [6] [7] . Miettinen et al reported that in small GISTs (< 2 cm) no metastasis occurred in 1765 cases, broken down into prognostic categories, with followup information [5] . In other words, it means that complete surgical resection of a GIST smaller than 2 cm has the potential to produce a 100% permanent cure without adjuvant therapy. However, not all gastric SELs are GISTs. Generally, most small gastric SELs were considered benign without su cient evidence [2, 8, 16] . erefore, the management of incidentally encountered gastric SELs smaller than 2cm remains controversial. Most gastric SELs smaller than 2 cm may be followed up endoscopically until they have grown or become symptomatic and the frequency of follow-up remains uncertain [16] . In this study, we found that malignant SELs have a 71% share of hypoechoic solid SELs measuring 1 to 2 cm, and that GISTs have a 67% share of them. Furthermore, postoperative risk assessment (modi ed-Fletcher's classi cation) of GISTs classi ed 23% as a moderate risk and 77% as a very low risk.
erefore, to perform early management, it is also desirable to pay special attention to small SEL groups as well as to the large ones.
In every kind of tumor including early gastric cancer, early diagnosis and early treatment is the best way to improve the quality of life of the patient. In early gastric cancer, histological con rmation is easily obtained using conventional endoscopic biopsy. However, it is di cult to obtain histologic diagnosis in the gastric SEL [7, 11, 16, 17] . Gastric SELs are frequently detected by EGD. However, the mucosal surface of SEL is usually normal, and the biopsy examination by conventional forceps at EGD is frequently negative. Deep biopsy procedures such as the unroo ng technique [18, 19] or mucosal incision assisted biopsy [20] were attempted to obtain su cient tissue sample, and showed a good diagnostic rate (85-100%) with su cient tissue volume. eir shortcomings are as follows: 1) di culty in obtaining a tissue sample of extraluminal growth pattern SEL, and 2) invasive and complicated procedures. Recently, Kannengiesser et al [21] reported that contrastenhanced harmonic EUS can discriminate GIST from benign lesions with high accuracy. However, diagnosis on the basis of EUS imaging is presumptive and cannot replace a histological diagnosis of SEL. In the diagnostic process of GIST, immunohistochemical analysis of tissue sample such as c-kit is vital for con rmation of this disease. erefore, at present EUS-FNA is a promising technique to obtain tissue samples from SELs with minimal risks [7, [11] [12] [13] [14] . In this study, the diagnostic rate ( rst session only) was 62% in gastric SELs measuring 1 to 2 cm, and the diagnostic rate including the sessions completed a er previous failure was improved to 73%.
ere were no complications. Although EUS-FNA for gastric SELs smaller than 2 cm was safe, the diagnostic rate (adequate sampling rate) was relatively low. To obtain more diagnostic tissue samples by EUS-FNA, various needles (25, 22, and19G needle sizes, trucut, procore, etc) have been developed. e reported diagnostic rate of EUS-FNA using such needles for GI tract SELs ranged from 52-93% [11] [12] [13] [14] [22] [23] [24] [25] [26] . Larghi et al [26] reported a good diagnostic rate (81.5%) of EUS-FNA using 19G needle and forward viewing linear echoendoscope for small SELs (less than 2 cm) in 27 patients. However, di erences in the EUS guided tissue sampling technique using various types of needles for tissue acquisition are still controversial. Further technical improvement and re nement of devices including needle and echoendoscope is needed to solve such problems.
In our 44 surgically resected cases (lesions smaller than 2 cm), the accuracy for EUS-FNA diagnosis using immunohistochemical analysis was 98%. The reported accuracy of preoperative diagnosis of EUS-FNA using immunohistochemical analysis for surgically resected GIST cases ranged from 85.2 to 97% without major complications [11] [12] [13] [14] . e diagnostic accuracy and safety of EUS-FNA using immunohistochemical analysis is excellent irrespective of tumor size. At present, EUS-FNA is the most accurate and safe preoperative histological test for small gastric SELs including GIST. Polkowski and Bergman [27] pointed out that most previous retrospective studies tended to overestimate the yield of EUS-FNA. In fact, non-surgically resected cases (benign lesion diagnosed by EUS-FNA such as leiomyoma or neurinoma, etc) were judged as correct diagnosis cases by follow-up study using imaging tests (no advance of the lesion, i.e. size up or metastasis, etc). erefore, there is a risk of malignant lesions such as GISTs to be misdiagnosed as benign lesions (leiomyoma or neurinoma, etc.), which leads to overestimating the diagnostic yield. However, diagnostic yield of EUS-FNA for surgically resected cases is accurate, because comparison between immunohistochemical analysis results of EUS-FNA specimen and that of surgically resected specimen is available.
In our institute, we previously designed an algorithm for early diagnosis of SELs using EUS-FNA, and have performed decision making according to this algorithm in the daily clinical setting (Fig. 1) [7] . In our algorithm, the indication for EUS-FNA is subepithelial hypoechoic solid tumor larger than 1 cm. e larger than 1 cm limit was determined by technical issues. Using the current EUS-FNA system including needles, it is di cult to puncture an intramural solid tumor smaller than 1 cm, and there is also a risk of seeding due to needle penetration of the small tumor. Surgical planning, including the type of surgery to be conducted, varies dramatically in relation to the histological diagnosis [7, [11] [12] [13] [14] . Accurate preoperative histological proof of gastric SELs using EUS-FNA facilitates the surgeon's decision-making for early local resection. For example, a patient with localized GIST can be cured with a wedge resection, or if the GIST is extensive, he can receive imatinib; however, a patient with SEL-like gastric cancer would undergo gastrectomy with lymph-node dissection. A patient with benign SEL could avoid surgery completely because of the con rmation of histological benignancy such as ectopic pancreas. In this study, appropriate decision making using EUS-FNA was made in 98% of patients. EUS-FNA thus evidently has a signi cant positive impact on the clinical management of patients by providing a de nitive histological diagnosis [11] . From the point of view of curability of gastric GIST, 2 cm is a promising line for obtaining a permanent cure using local resection [5] . We previously reported a postoperative hepatic metastasis case with 2.5 cm gastric GIST [7] . is patient died 6 years a er surgery, even a er using imatinib. In our gastric GIST series smaller than 2 cm, pre-therapeutic imaging modalities revealed no metastasis. Furthermore, there was no post-operative local or distant recurrence in the follow-up study. erefore, we believe that early diagnosis of 1 to 2 cm gastric SEL using EUS-FNA is an encouraging approach to improving the management of patients with gastric GIST.
However, the majority of GISTs < 2 cm simply do not evolve to metastatic disease at follow-up [16] . A recent update of the National Comprehensive Cancer Network Guidelines on the management of GISTs recommends that incidentally encountered small asymptomatic gastric GISTs (less than 2 cm) with no high-risk EUS features can be managed conservatively with endoscopic surveillance at 6 to 12 months intervals [2, 24] . On the contrary, accurate di erential diagnosis between benign and malignant GIST is considered to be very di cult both by imaging tests and by pathological examinations. us, European (ESMO) and Japanese GIST guidelines recommend surgical resection when SEL is diagnosed as an immunohistologically con rmed GIST even if < 2 cm [8] [9] [10] . At the moment, the decision to indicate surgery or watch and wait are both reasonable a er su cient discussion with the patient. Further extensive clinical studies are needed to clarify this point.
CONCLUSION
EUS-FNA with immunohistochemical analysis is a safe and accurate histological test in the pre-therapeutic diagnosis of gastric SELs smaller than 2 cm. EUS-FNA for gastric SELs smaller than 2 cm is a promising option that enables us to perform early diagnosis and early treatment of this condition.
